Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1998-12-07
2000-05-30
O'Sullivan, Peter
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514463, 514510, 549432, 554 63, 560174, 564223, A61K 31167
Patent
active
060691743
ABSTRACT:
A composition for the upregulation of expression of cell antigens, without inducing shedding, which comprises a protein kinase C activator is provided by this invention. Further provided by this invention is a method of detecting and treating tumor cells comprising contacting tumor cells with an effective amount of a protein kinase C activator for the upregulation of expression of antigens of tumor cells, without inducing antigen shedding, and detecting the presence of said antigen or then further contacting said tumor cells with an effective amount of an antibody directed to said antigen.
REFERENCES:
patent: 4925649 (1990-05-01), Counsell et al.
patent: 5681860 (1997-10-01), Fisher et al.
Barton, K., et al. (1989) "The effects of the antitumor agent mazerein on the cytotoxic capacity and oxidative metabolism of human blood cells." Chemical Abstracts 111: abstract No. 146415w, Invest. New Drugs (1989) 7: 179-188.
Celada, A. and Maki, R.A. (1991) "IFN-.gamma. induces the expression of the genes for MHC Class II I-A.sub..beta. and tumor necrosis factor through a protein kinase C-independent pathway." J. Immunol. 146 : 114-120.
Downey, G.P. et al. (1992) "Phorbol ester-induced actin assembly in neutrophils: role of protein kinase C. " J. Cell Biol. 116: 695-706.
Fisher, P.B. and Rowley, P.T. (1991) "Regulation of growth, differentiation and antigen expression in human tumor cells by recombinant cytokines: potential applications for the differentiation therapy of human cancer." In: Waxman, S., Rossi, B.B., and Takaku, F. (eds.) Status of differentiation therapy of cancer, vol. II Raven Press, New York, pp. 201-213.
Fuith, L.C., et al. (1991) "Enhancement of CA 125 expression by interferon-gamma in ovarian carcinoma xenografts." J. Tumor Marker Oncology 6: 85-89.
Giacomini, P., et al. (1984) "Modulation by recombinant DNA leukocyte (.alpha.) and fibroblast (.beta.) interferons of the expression and shedding of HLA- and tumor- associated antigens by human melanoma cells." J. Immunol. 133: 1649-1655.
Greiner, J.W., et al. (1984) "Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte .alpha.-interferon treatment." Cancer Res. 44: 3208-3213.
Greiner, J.W., et al. (1986) "Differential effects of recombinant human leukocyte interferons on cell surface antigen expression." Cancer Res. 46: 4894-4990.
Guarini, L. et al., "Modulation of the Antigenic Phenotype of Human Melanoma Cells by Differentiation-inducing and Growth-Suppressing Agents," Pigment Cell Res. Suppl. 2 (1992) 123-131 (Exhibit 5).
Harada, Y., et al. (1993) "Tumor differentiation and immunohistochemical markers in adenocarcinoma." Chemical Abstracts 118: abstract No. 57252t, Wakayama Igaku (1992) 42: 759-765.
Leon, J.A., et al. (1992) "Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and reombinant human interferons." Cancer Immunology Immunotherapy 35: 315-324.
Murray, J.L., et al. (1990) "Recombinant .alpha.-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo." J. Biol. Resp. Mod. 9: 556-563.
Redy L.L., et al. (1990) "Evidence that weak promotion of carcinogen-initiated cells prevents their progression to malignancy." Carcinogenesis 11: 2123-2126.
Tony, H.-P., "Differential Signal Requirement for Upregulation of HLA-Class II Molecules in Human Lymphoma B Cells," Hematologic Pathology, vol. 7, No. 2 (Feb. 1993) 79-90 (Exhibit 6).
Wender, P.A., et al. (1986) "Analysis of the phorbol ester pharmacophore on protein kinase C as a guide to the rational design of new classes of analogs." Proc. Natl. Acad. Sci. (USA) 83: 4214-4218.
Fisher Paul B.
Leon Jorge A.
O'Sullivan Peter
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Protein kinase C activators and their use in increasing expressi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein kinase C activators and their use in increasing expressi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase C activators and their use in increasing expressi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1910753